About 23andMe—and researchers.
Expanding our services to help you gain genetic insights.
23andMe started a revolution in genomics by helping people access, understand and benefit from their personal genetic information.
Now we’re offering Genotyping Services for Research – combining the simplicity of end-to-end genotyping with the ability to deliver personalized, easy-to-understand genetic reports directly to your research participants.
23andMe, Inc. is the leading personal genetics company. Founded in 2006, the mission of the company is to help people access, understand and benefit from the human genome. 23andMe has more than 1 million customers worldwide, with over 80 percent consented to participate in research. 23andMe, Inc. is located in Mountain View, California.
In 2015, 23andMe became the first and only company to receive FDA marketing authorization for our direct-to-consumer genetic test for Bloom Syndrome.
Along with the authorization, the FDA stated that it intended to classify autosomal recessive carrier status screening tests* as class II exempt, subject to general and special controls. As a result, 35 additional carrier status reports in the 23andMe experience meet these FDA standards. Moving forward, 23andMe will continue to seek FDA authorization of new reports within the carrier status and other categories.
Within the 23andMe platform, data are segmented across logical database systems in a way that prevents re-identifiability, even among essential privileged support staff. It also facilitates de-identification of research participants as segments of their data are moved to research or customer care.